FDA accuses firm of selling unapproved drugs
This article was originally published in The Tan Sheet
Executive Summary
Under a consent decree with FDA, Risingsun Health and the Center for Complimentary and Alternative Health in Livingston, Mont., agree to hire an independent expert for pre-market review of product claims and to certify the claims are compliant. The decree, which also prohibits the firms from selling unapproved new drugs, was filed in the U.S. District Court for the District of Montana and resolves charges the firm sold ineffective products. Prior to signing the decree, Risingsun made and distributed unapproved new drugs, including Black Salve, Cancema and Can-Support, purported to treat cancer, asthma, anemia and epilepsy, FDA said Oct. 13
You may also be interested in...
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
The Race To Vaccinate The World Against COVID-19
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: